Vaccination with LAMP-based constructs achieves therapeutic outcomes by inducing active humoral immunity and a cell mediated response against a targeted biological agent. LAMP-Vax™ vaccines are safe, effective, and inexpensive to manufacture. Through academic and industry partners, LAMP vaccine formulations have been tested in clinical trials for a variety of cancers and have been shown to be safe, well-tolerated, and immunogenic.
ITI's clinical development strategy is to develop next generation LAMP Technology allergy immunotherapy formulations for commercialization. The Company's first commercial target is Japanese red cedar, which affects 35 million Japanese. Second generation LAMP vaccines are in development for commercialization, including a peanut allergy vaccine and a broadly therapeutic multivalent pollen allergy product.
ITI has completed preclinical development of JRC-LAMP-Vax and in Q2 2012 completed dosing under a Phase 1 safety study in Japanese Red Cedar CryJ2-allergen allergic patients. In Q4 2013, ITI will to seek authorization from the FDA to proceed with its next clinical study, a Ph I/II testing multivalent JRC-LAMP-Vax, and intends to begin dosing patients during Q4 2013/Q1 2014.. Through allergy clinical trials, ITI can quickly validate the mechanism of action of its vaccine formulations providing insight into the value of applying LAMP Technology to other disease areas.
The pipeline below illustrates the current status of Immunomic Therapeutics' clinical development program. For more indication-specific information, click the links below.
Immunomic Therapeutics, Inc.
Headquarters: 1214 Research Blvd, Suite 201, Hershey, PA 17036
Lab: 15010 Broschart Rd. Ste. 110, Rockville, MD 20850
© 2007-2013 Immunomic Therapeutics, Inc.
All rights reserved